166 related articles for article (PubMed ID: 36752506)
21. Asparaginase activities during intensified treatment with pegylated
Lanvers-Kaminsky C; Niemann A; Eveslage M; Beck J; Köhnke T; Martin S; de Wit M; Spriewald B; Hauspurg H; Hoelzer D; Boos J; Gökbuget N
Leuk Lymphoma; 2020 Jan; 61(1):138-145. PubMed ID: 31480965
[TBL] [Abstract][Full Text] [Related]
22. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
23. Pancreas-related persisting sequelae in ALL survivors with a history of asparaginase-associated pancreatitis: A part of the ALL-STAR study.
Skipper MT; Birkebæk N; Jensen RB; Rank CU; Tuckuviene R; Wehner PS; Lambine TL; Hørlyck A; Schmiegelow K; Frandsen TL; Andrés-Jensen L; Albertsen BK
Eur J Haematol; 2024 Jun; 112(6):944-956. PubMed ID: 38351310
[TBL] [Abstract][Full Text] [Related]
24. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
[TBL] [Abstract][Full Text] [Related]
25. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
Gupta S; Wang C; Raetz EA; Schore R; Salzer WL; Larsen EC; Maloney KW; Mattano LA; Carroll WL; Winick NJ; Hunger SP; Loh ML; Devidas M
J Clin Oncol; 2020 Jun; 38(17):1897-1905. PubMed ID: 32275469
[TBL] [Abstract][Full Text] [Related]
26. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
Avramis VI; Tiwari PN
Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
[TBL] [Abstract][Full Text] [Related]
27. Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol.
Wolthers BO; Frandsen TL; Abrahamsson J; Albertsen BK; Helt LR; Heyman M; Jónsson ÓG; Kõrgvee LT; Lund B; Raja RA; Rasmussen KK; Taskinen M; Tulstrup M; Vaitkevičienė GE; Yadav R; Gupta R; Schmiegelow K
Leukemia; 2017 Feb; 31(2):325-332. PubMed ID: 27451978
[TBL] [Abstract][Full Text] [Related]
28. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.
Vieira Pinheiro JP; Müller HJ; Schwabe D; Gunkel M; Casimiro da Palma J; Henze G; von Schütz V; Winkelhorst M; Würthwein G; Boos J
Br J Haematol; 2001 Apr; 113(1):115-9. PubMed ID: 11328290
[TBL] [Abstract][Full Text] [Related]
29. Successful use of enteral nutrition for asparaginase-induced pancreatitis in children with acute lymphoblastic leukemia and lymphoblastic lymphoma: A case series.
Le C; Hamby T; Ray A; Hill R
Nutrition; 2022 Mar; 95():111559. PubMed ID: 35032734
[TBL] [Abstract][Full Text] [Related]
30. Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.
Wolthers BO; Frandsen TL; Baruchel A; Attarbaschi A; Barzilai S; Colombini A; Escherich G; Grell K; Inaba H; Kovacs G; Liang DC; Mateos M; Mondelaers V; Möricke A; Ociepa T; Samarasinghe S; Silverman LB; van der Sluis IM; Stanulla M; Vrooman LM; Yano M; Zapotocka E; Schmiegelow K;
Lancet Oncol; 2017 Sep; 18(9):1238-1248. PubMed ID: 28736188
[TBL] [Abstract][Full Text] [Related]
31. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
[TBL] [Abstract][Full Text] [Related]
32. Predicting asparaginase-associated pancreatitis.
Knoderer HM; Robarge J; Flockhart DA
Pediatr Blood Cancer; 2007 Oct; 49(5):634-9. PubMed ID: 16937362
[TBL] [Abstract][Full Text] [Related]
33. A systems approach points to a therapeutic role for retinoids in asparaginase-associated pancreatitis.
Tsai CY; Saito T; Sarangdhar M; Abu-El-Haija M; Wen L; Lee B; Yu M; Lipata DA; Manohar M; Barakat MT; Contrepois K; Tran TH; Theoret Y; Bo N; Ding Y; Stevenson K; Ladas EJ; Silverman LB; Quadro L; Anthony TG; Jegga AG; Husain SZ
Sci Transl Med; 2023 Mar; 15(687):eabn2110. PubMed ID: 36921036
[TBL] [Abstract][Full Text] [Related]
34. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
35. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Vieira Pinheiro JP; Lanversa C; Würthwein G; Beier R; Casimiro da Palma J; von Stackelberg A; Boos J
Leuk Lymphoma; 2002 Oct; 43(10):1911-20. PubMed ID: 12481884
[TBL] [Abstract][Full Text] [Related]
36. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
[TBL] [Abstract][Full Text] [Related]
37. Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Gottschalk Højfeldt S; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Marquart HV; Vaitkeviciene G; Lepik K; Heyman M; Schmiegelow K; Albertsen BK
Blood; 2021 Apr; 137(17):2373-2382. PubMed ID: 33150360
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study.
Würthwein G; Lanvers-Kaminsky C; Gerss J; Möricke A; Zimmermann M; Stary J; Smisek P; Attarbaschi A; Nath C; Zucchetti M; Rizzari C; Schrappe M; Boos J;
Ther Drug Monit; 2020 Jun; 42(3):435-444. PubMed ID: 32022785
[TBL] [Abstract][Full Text] [Related]
39. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.
Kearney SL; Dahlberg SE; Levy DE; Voss SD; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2009 Aug; 53(2):162-7. PubMed ID: 19405141
[TBL] [Abstract][Full Text] [Related]
40. Acid-suppressing Drugs and a Low 1 Level of Antithrombin as Risk Factors for L-Asparaginase-associated Pancreatitis: A Case-control Study in the Japan Association of Childhood Leukemia Study (JACLS).
Hashii Y; Yoshida M; Hara J; Nishimura S; Yumura-Yagi K; Horibe K; Nakahata T
J Pediatr Hematol Oncol; 2018 Jul; 40(5):374-378. PubMed ID: 29697579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
